Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Atomoxetine→

Atomoxetine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
83015-26-3
Molecular formula
C17H21NO
Molecular weight
255.35 g/mol
Drug class
Norepinephrine Reuptake Inhibitor
Mechanism of action
Norepinephrine Uptake Inhibitors
Indications / reported uses
  • Attention Deficit Disorder with Hyperactivity
View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Atomoxetine Environmental Risk Assessment (ERA) (the Atomoxetine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.